Anticipated Financial Release: Projected Insights Regarding Becton, Dickinson and Company's Financial Statement
The medical technology giant, Becton, Dickinson and Company (BDX), is gearing up to reveal its third-quarter earnings for 2025 on August 7, 2025. As of July 28, the actual report remains unpublished [2][3].
Analysts anticipate the earnings per share (EPS) to range around $3.42 to $3.44, with some variations. For instance, William Blair forecasts an EPS of $3.43, down from an earlier estimate of $3.52 [1][3]. The expected EPS represents a slight decrease compared to the year-ago quarter EPS of approximately $3.50 [3][1].
Revenue estimates for Q3 2025 are around $5.49 to $5.50 billion, signifying moderate growth projections compared to the previous year [1][4].
In the most recent quarterly report, BDX posted an EPS of $3.35, beating an estimate of $3.28, with $5.27 billion in revenue, slightly below an expected $5.35 billion [1]. However, this was not for Q3 2025 but an earlier quarter.
Out of 17 analysts covering the stock, seven advise a "Strong Buy" rating, one suggests a "Moderate Buy," and nine give a "Hold." Despite this, the software recall in BDX's Alaris infusion pump systems has caused underperformance [2].
The software issues in the Alaris Systems Manager and Care Coordination Engine Infusion Adapter can cause delayed responses and potentially incorrect therapy administration, posing risks to patient safety [2].
BDX shares have decreased by 22.6% during this period, and the stock has underperformed the S&P 500 Index's 17.3% gains over the past 52 weeks [2].
Despite the challenges, BDX has consistently surpassed Wall Street's EPS estimates in its last four quarterly reports [2]. The company expects full-year adjusted EPS in the range of $14.06 to $14.34, and expects revenue in the range of $21.8 billion to $21.9 billion [2].
BDX develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products [2]. The company is valued at $52.3 billion by market cap [2].
Analysts predict BDX will report a profit of $3.42 per share for the third quarter of 2025 [1]. For the full year, they expect BDX to report EPS of $14.17, up 7.8% from $13.14 in fiscal 2024 [1].
BDX's adjusted EPS of $3.35 in Q2 exceeded Wall Street's expectations of $3.28 [1]. This profit is expected to be a 2.3% decrease from the $3.50 per share reported in the year-ago quarter [1].
The average analyst price target for BDX stock is $213.71, indicating a potential upside of 16.4% from the current levels [2]. With an overall "Moderate Buy" rating, analysts have a reasonably bullish consensus opinion on BDX stock [2].
Disclosure: Neha Panjwani did not have positions in any of the securities mentioned in the article at the date of publication.
[1] Yahoo Finance [2] MarketWatch [3] Seeking Alpha [4] The Motley Fool
- The medical technology company, Becton, Dickinson and Company (BDX), is anticipated to report a profit of $3.42 per share for the third quarter of 2025, according to analysts.
- BDX's expected full-year EPS for 2025 is $14.17, which represents a 7.8% increase from its fiscal 2024 EPS of $13.14.
- BDX's primary business involves developing, manufacturing, and selling medical supplies, devices, laboratory equipment, and diagnostic products, with a market cap value of $52.3 billion.
- The average analyst price target for BDX stock is $213.71, suggesting a potential upside of 16.4% from current levels, and the overall consensus opinion on BDX stock is relatively positive, with an "Moderate Buy" rating.
